Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

HIV Prevention Toolkit for HIV-negative Male Couples

NCT02494817
Conditions
HIV
Interventions
Male Couples Agreement Project
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
HIV Infections, Opioid Use
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prevention of Infection With HIV-1
Interventions
ibalizumab (biologic/MAb) for SC Injection or placebo
Biological
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 3 more
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sunitinib malate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Conditions
Syphilis
Interventions
Benzathine Penicillin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more
Conditions
Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea, Chlamydia, Syphilis, Sexually Transmitted Infection, Integrated Care, Medications for Opioid Use Disorder
Interventions
Integrated care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2029
U.S. locations
1
States / cities
Northport, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers

Microbicide Safety and Acceptability in Young Men

NCT01283360
Conditions
High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions
HEC Placebo Gel, Tenofovir 1% Gel
Other · Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults

NCT04132830
Conditions
HIV-exposed Uninfected
Interventions
In Utero HIV Exposure, No In Utero HIV Exposure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions
Interventions
Radiofrequency Ablation (RFA) using the HALO Ablation System
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions
Artesunate, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Completed No phase listed Observational Accepts healthy volunteers

Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs

NCT00245531
Conditions
Human Immunodeficiency Virus Positive or Negative
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy, Contraception, Contraceptive Usage, Women
Interventions
VR: 200 mg DPV + 320 mg LNG
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Multimedia WORTH With Black Drug-Involved Women on Probation

NCT02391233
Conditions
Sexually Transmitted Infections, HIV, Gonorrhea, Trichomonas, Chlamydia Trachomatis, Drug Use
Interventions
E-WORTH, Streamlined HIV Testing
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

NCT00107042
Conditions
Hepatitis B
Interventions
Recombivax, Twinrix
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 17 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more